Biofortis
Addison, Illinois, 60101, United States
NCT Number: NCT04707989
The objective of this study is to capture information on tolerance and safety of a ketone-promoting food ingredient in healthy adults.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Not applicable
Addison, Illinois, 60101, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Novel proprietary food ingredient (#1) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.
Previously characterized proprietary food ingredient (#2) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.
Beverage that is matched to ketone-promoting food ingredient #1 beverage for appearance, taste, texture and volume. Does not contain ketones or ketone precursors.
Time frame: Day From baseline to Day 28
Difference between experimental arm (ketone promoting food ingredient #1) vs placebo in composite score of tolerance, assessed by twice daily tolerance questionnaires completed at home.
Subjects complete a tolerance questionnaire twice daily, to assess the presence of 10 symptoms before and 4-6h after consuming the study beverage. Questionnaire ranks severity (None, mild, moderate, severe) and incidence (usually, somewhat more than usual, much more than usual). Answers are assigned a numerical value, where higher score is a greater severity and incidence of symptoms. The difference is calculated between the pre- and post- beverage questionnaire for a daily score. Daily scores for the duration of the study are added together to give a single composite score for the whole study period.
Time frame: Days 0, 7 and 14
Difference between experimental arm (ketone promoting food ingredient #1) vs placebo in composite scores of tolerability, assessed by a tolerance questionnaire at 1h after beverage consumption at clinic visits.
Subjects complete a tolerance questionnaire twice, to assess the presence of 10 symptoms before and 1h after consuming the study beverage. Questionnaire ranks severity (None, mild, moderate, severe) and incidence (usually, somewhat more than usual, much more than usual). Answers are assigned a numerical value, where higher score is a greater severity and incidence of symptoms. The difference is calculated between the pre- and post- beverage questionnaire for a score representing acute tolerance.
Time frame: From baseline to Day 28
Difference between experimental arm (ketone promoting food ingredient #1) vs placebo in the composite scores of the stimulatory and sedative subscale using the Brief Biphasic Alcohol Effect Scale (B-BAES); completed twice daily at home.
B-BAES presents 6 items in alphabetical order, and subjects rank them on an 11 point scale, from 0 = not at all to 10 = extremely.
The difference is calculated between the pre- and post- beverage questionnaire for a daily score. Daily scores for the duration of the study are added together to give a single composite score for the whole study period.
Rueger, S. Y. and A. C. King (2013). "Validation of the brief Biphasic Alcohol Effects Scale (B-BAES)." Alcohol Clin Exp Res 37(3): 470-476.
Time frame: From baseline to Day 28
Change from baseline Day 28 in the incidence of abnormal laboratory test results
Time frame: From baseline to Day 28
Difference between active comparator arm (ketone promoting food ingredient #2) vs placebo in composite score of tolerance, assessed by twice daily tolerance questionnaires completed at home.
Subjects complete a tolerance questionnaire twice daily, to assess the presence of 10 symptoms before and 4-6h after consuming the study beverage. Questionnaire ranks severity (None, mild, moderate, severe) and incidence (usually, somewhat more than usual, much more than usual). Answers are assigned a numerical value, where higher score is a greater severity and incidence of symptoms. The difference is calculated between the pre- and post- beverage questionnaire for a daily score. Daily scores for the duration of the study are added together to give a single composite score for the whole study period.
Time frame: Days 0, 7 and 14
Difference between active comparator arm (ketone promoting food ingredient #2) vs placebo in composite scores of tolerability, assessed by a tolerance questionnaire at 1h after beverage consumption at clinic visits.
Subjects complete a tolerance questionnaire twice, to assess the presence of 10 symptoms before and 1h after consuming the study beverage. Questionnaire ranks severity (None, mild, moderate, severe) and incidence (usually, somewhat more than usual, much more than usual). Answers are assigned a numerical value, where higher score is a greater severity and incidence of symptoms. The difference is calculated between the pre- and post- beverage questionnaire for a score representing acute tolerance.
Time frame: From baseline to Day 28
Difference between active comparator arm (ketone promoting food ingredient #2) vs placebo in the composite scores of the stimulatory and sedative subscale using the Brief Biphasic Alcohol Effect Scale (B-BAES); completed twice daily at home.
B-BAES presents 6 items in alphabetical order, and subjects rank them on an 11 point scale, from 0 = not at all to 10 = extremely.
The difference is calculated between the pre- and post- beverage questionnaire for a daily score. Daily scores for the duration of the study are added together to give a single composite score for the whole study period.
Rueger, S. Y. and A. C. King (2013). "Validation of the brief Biphasic Alcohol Effects Scale (B-BAES)." Alcohol Clin Exp Res 37(3): 470-476.
BHB Therapeutics, Ireland LTD
Industry
A Randomized, Placebo Controlled, Study to Evaluate the Tolerance and Safety of a Ketone- Promoting Food Ingredient in Healthy Men and Women
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07302477
Adverse Event, Growth
Chak Four Hundred Fifty-four, Pakistan
View Trial DetailsNCT04576507
Cannabis, Chemically-Induced Disorders
New York, United States
View Trial DetailsNCT05978908
Safety Issues, Tolerance
Berlin, New Jersey, United States
View Trial DetailsNCT06232460
Tolerance
Chicago, Illinois, United States
View Trial Details